Dfn-15
Low Back Pain
First Affiliated Hospital of Zhejiang UniversityPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Low Back Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxycodone Brigham and Women's Hospital | Phase 4 | BBB |
Tapentadol Grünenthal GmbH | Phase 4 | BBB |
FENTANYL Balnear and Rehabilitation Sanatorium Techirghiol | Phase 4 | BBB |
Buprenorphine BioDelivery Sciences International | Phase 4 | BBB |
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE Grünenthal GmbH | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →